- Threshold Suspended Device Systems
- Treat to Range/Control to Range (TTR/CTR)
- Treat to Target/ Control to Target (TTR/CTT)
Artificial Pancreas Device Systems Market was valued at USD 97.8 million in 2022 and poised to grow at a CAGR of 12.5% from 2023 to 2029. Artificial pancreas device systems are medical devices which links glucose to an insulin paracetamol infusion pump, monitor reading. These devices are meant to improve glycaemic control in patients with insulin-dependent diabetes and in control of nocturnal hypoglycaemia. The pancreas will secrete insulin and glucagon. Type-I diabetes occurs when the pancreas produces little or none of the insulin needed to regulate blood glucose. Type-II diabetes occurs when the pancreas does not produce enough insulin or the body becomes resistant to insulin that is present. The burgeoning incidence of diabetes is the major factor, which is expected to trigger the artificial pancreas devices market. As per WHO, global diabetes cases were increased from 108 Mn to 422Mn from 1980 to 2014. As per, Juvenile Diabetes Research Foundation in 2015, around 1.5Mn cases of type-I were found. Furthermore, growing geriatric population, increase in the incidence of lifestyle disorders and obesity which further leads diabetes which in turns propel the growth of artificial pancreas devices market. However, the insulin used in artificial pancreas devices takes the long duration to get absorb, lack of awareness, a dearth of skilled professionals are the factors which are restraining the growth of Artificial Pancreas Device Systems Market. Favourable regulations, increased collaborations coupled with rising prevalence of diabetes are expected to boost the market. FDA is collaborating with government and private research institutions to enhance the clinical studies and to speed up the development of innovative technologies in artificial pancreas device systems.
Fastest Growing Market
Technological innovations and product developments are propelling the market growth such as Tandem diabetes care outline its plans in APDS market by initiating R&D phase of its artificial pancreas system. Bigfoot Biomedicals goal is to create a pump sensor union therapy which could be much simpler than the current counterparts. Beta bionics developed iLet Bionic Pancreas System which delivers both insulin and glucagon in type-1DM patients. Hence, all these products from the major players will be available soon which could increase the growth of the market.
The artificial pancreas device systems market size was valued at USD 97.8 million in 2022
Increasing Prevalence of Diabetes
Europe is the fastest-growing for artificial pancreas device systems market